Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 3791-3796

  Chu, Stephanie W L ^a   Badar, Samina ^a   Morris, David L ^a   Pourgholami, Mohammad H ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Albendazole; Ovarian cancer; Paclitaxel; Resistance; Tubulin

Indexed keywords

ALBENDAZOLE; COLCHICINE; PACLITAXEL;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN 1A9PTX22; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN TISSUE; IC 50; IMMUNOFLUORESCENCE; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; OVARY CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ALBENDAZOLE; CELL GROWTH PROCESSES; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICROTUBULES; OVARIAN NEOPLASMS; PACLITAXEL; TUBULIN; TUBULIN MODULATORS; TUMOR CELLS, CULTURED;

EID: 71949100927     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Cannistra SA: Cancer of the Ovary. N Engl J Med 351: 2519-2529, 2004.
2. Davy M: Ovarian cancer - diagnosis and management. Aust Fam Physician 36: 130-133, 2007.
3. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979. (Pubitemid 9114288)
4. Amos LA and Lowe J: How Taxol(R) stabilises microtubule structure. Chem Biol 6: R65-R69, 1999.
5. van der Zee AGJ, Hollema HH, de Bruijn HWA, Willemse PHB, Boonstra H, Mulder NH, Aalders JG and de Vries EGE: Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol 58: 165-178, 1995.
6. Cook GC: Use of benzimidazole chemotherapy in human helminthiases: Indications and efficacy. Parasitol Today 6: 133-136, 1990.
7. Lacey E: Mode of action of benzimidazoles. Parasitol Today 6: 112-115, 1990.
8. Rolin S, Amri HS-E, Batt A-M, Levy M, Bagrel D and Siest, G: Study of the in vitro bioactivation of albendazole in human liver microsomes and hepatoma cell lines. Cell Biol Toxicol 5: 1-14, 1989. (Pubitemid 19114004)
9. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P and Morris DL: In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 165: 43-49, 2001.
10. Khalilzadeh A, Wangoo KT, Morris DL and Pourgholami MH: Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. Biochem Pharmacol 74: 407-414, 2007. (Pubitemid 46963241)
11. Pourgholami MH, Yan Cai Z, Lu Y, Wang L and Morris DL: Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 12: 1928-1935, 2006.
12. Giannakakou P, Sackett DL, Kang Y-K, Zhan Z, Buters JTM, Fojo T and Poruchynsky MS: Paclitaxel-resistant human ovarian cancer cells have mutant beta -tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118-17125, 1997. (Pubitemid 27289821)
13. Poruchynsky MS, Kim J-H, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL and Fojo T: Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in α or β-tubulin and increased microtubule stability. Biochem 43: 13944-13954, 2004. (Pubitemid 39482744)
14. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980.
15. Dumontet C and Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061-1070, 1999. (Pubitemid 29109340)
16. Orr GA, Verdier-Pinard P, McDaid HM and Horwitz S: Mechanisms of taxol resistance related to microtubules. Oncogene 22: 7280-7295, 2003. (Pubitemid 37487160)
17. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M and Horwitz S: Taxol-resistant epithelial ovarian tumours are associated with altered expression of specific beta-tubulin isotypes J Clin Invest 100: 1282-1293, 1997. (Pubitemid 27386315)
18. Martin RJ: Modes of action of anthelmintic drugs. Vet J 154: 11-34, 1997.
19. Friedman PA and Platzer EG: Interaction of anthelmintic benzimidazoles and benzimidazole derivatives with bovine brain tubulin. Biochim Biophys Acta 544: 605-614, 1978.
20. Friedman PA and Platzer EG: Interaction of anthelmintic benzimidazoles with Ascaris suum embryonic tubulin. Biochim Biophys Acta 630: 271-278, 1980.
21. Lacey E and Watson TR: Structure-activity relationships of benzimidazole carbamates as inhibitors of mammalian tubulin, in vitro. Biochem Pharmacol 34: 1073-1077, 1985. (Pubitemid 15054415)
22. Lubega GW and Prichard RK: Interaction of benzimidazole anthelmintics with Haemonchus contortus tubulin: binding affinity and anthelmintic efficacy. Exp Parasitol 73: 203-213, 1991.
23. Clément M-J, Rathinasamy K, Adjadj E, Toma F, Curmi PA and Panda D: Benomyl and colchicine synergistically inhibit cell proliferation and mitosis: Evidence of distinct binding sites for these agents in tubulin. Biochem 47: 13016-13025, 2008.
24. Schiff PB and Horwitz SB: Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochemistry 20: 3247-3252, 1981.
25. Horwitz SB: Mechanism of action of taxol. Trends Pharmacol Sci 13: 134-136, 1992.